Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.52 |
| ▸ | NQO2 | P16083 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629557 | 1.00 | PLA2G2A (0.52) | PLA2G2ANQO2RXFP1MRGPRX4KDM4E | |
| SCHEMBL5638035 | 0.88 | EGFR (0.47) | PLA2G2ANQO2RXFP1MRGPRX4NR4A2 | |
| SCHEMBL16832481 | 0.87 | PLA2G2A (0.63) | PLA2G2ANQO2RXFP1KDM4ENR4A2 | |
| SCHEMBL2908784 | 0.87 | PLA2G2A (0.51) | PLA2G2ANQO2RXFP1MRGPRX4KDM4E | |
| SCHEMBL28100420 | 0.85 | PLA2G2A (0.58) | PLA2G2ANQO2RXFP1KDM4ENR4A2 | |
| SCHEMBL22396163 | 0.85 | L3MBTL1 (0.56) | NQO2RXFP1KDM4ENR4A2ALDH1A1 | |
| SCHEMBL13919628 | 0.85 | NQO2 (0.45) | PLA2G2ANQO2KDM4E | |
| SCHEMBL3281931 | 0.85 | PLA2G2A (0.49) | PLA2G2ANQO2KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL28071639 | 0.84 | PLA2G2A (0.54) | PLA2G2ANQO2RXFP1KDM4ENR4A2 | |
| SCHEMBL3281879 | 0.83 | KDM4E (0.60) | NQO2KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| CN-1882568-B | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB | 2012-03-28 | — | — | CN | disclosed |
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| CN-1882568-A | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-12-20 | — | — | CN | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1664025-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | PLA2G2A 3888/4885NQO2 776/4885RXFP1 2964/4885 |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK6, CDK2 | PLA2G2A 2723/4885NQO2 809/4885RXFP1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.